MarginsXMarginsX
Home › Markets › Health Care › MCRB

Seres Therapeutics Inc. (MCRB)

MCRB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.41
+0.71% on the day
Market cap
$14.4M
Nano cap
Revenue · 2025
$789K
Prior year not contiguous
Net income · 2025
$5.7M
721.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1609809/000119312526103276/0001193125-26-103276-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMCRB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001609809
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$789K
Net income$5.7M
Operating income-$94.0M
Net margin721.9%
Operating margin-11910.1%
Revenue growthNo prior-year revenue to compare
Cash$45.8M
Total assets$138.2M
P/E (computed)2.5×
P/S (computed)18.2×

Warning signs

Cash runway
3.3 months
$17.5M cash at September 30, 2026
Share count, 1 year
+12.7%
2025-10-31 to 2026-11-02 · +57.7% over 3 years
Going-concern doubt
Yes
10-Q filed November 4, 2026
Insider net buying, 12 months
-$55K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-04
Cash and burn$17.5M cash; operating cash flow -$16.0M a quarter.Report 2026-09-30
Shares outstanding10,195,031 (2026-11-02); 9,046,519 a year earlier; 129,257,199 three years earlier. 3y figure adjusted for split (1-for-20 overall).Cover page 2026-11-02
Reverse splits, 3 years1; latest 1-for-20 on 2025-04-22Source 2025-04-22
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-04
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $55K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$593K-$16.3M-$10.5M$17.5MNo debt tags$2.1M10-Q 2026-11-04
Q2 2026
2026-06-30
$736K$4.6M-$22.4M$15.6MNo debt tags$1.9M10-Q 2026-08-05
Q1 2026
2026-03-31
$358K-$19.9M-$16.4M$29.8MNo debt tags$1.1M10-Q 2026-05-05
Q4 2025
2025-12-31
$438K-$15.3M-$14.7M$45.8MNo debt tags$789K10-K 2026-03-12
Q3 2025
2025-09-30
$351K$8.2M$2.2M$47.6MNo debt tags$351K10-Q 2026-11-04
Q2 2025
2025-06-30
$0-$19.9M-$13.3M$45.4MNo debt tags$010-Q 2026-08-05
Q1 2025
2025-03-31
$0$32.7M$26.9M$58.8MNo debt tags$010-Q 2026-05-05
Q4 2024
2024-12-31
$0-$15.6M-$38.9M$30.8MNo debt tags$010-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-08-13
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 724 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-29.3%
1 month-44.7%
3 months-68.8%
Year to date-90.6%
1 year-91.6%
From 52-week high-95.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M
ALLRAllarity Therapeutics Inc.$0.8752-8.24%$13.9M
MRKRMarker Therapeutics Inc.$0.8286-4.76%$13.8M
PBMPsyence Biomedical Ltd. Common Shares$2.83-11.56%$15.0M
BOLTBolt Biotherapeutics Inc.$5.80-4.61%$15.1M
AKTXAkari Therapeutics plc ADS$6.51-4.26%$15.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier